Hyperhidrosis sufferers might be one step closer to having an easy-to-use treatment for what can often be an embarrassing condition. Thanks to Dermira Inc., the problem of excessive sweating might be able to be treated more easily via its experimental topical therapy.
Dermira is a biopharmaceutical company that is aimed at developing and commercialising innovative topical therapies to improve the lives of patients.
The company recently released the results of from its trials into its topical, anticholinergic product, which is in development to treat primary axillary hyperhidrosis.
According to a statement made by Dermira, the product statistically demonstrated making significant improvements for both the “co-primary endpoints and secondary endpoints sweat severity and production – in the ATMOS-2 trial for the treatment of primary axillary hyperhidrosis compared with a vehicle.”
Thomas Wiggans, MBA, chairman and CEO of Dermira shared his enthusiasm of the results.
“These results from the ATMOS-1 and ATMOS-2 trials bring us a step close to offering DRM04 as a once-daily, topical treatment for the millions of people who suffer from primary axillary hyperhidrosis, an undertreated skin condition.”
There were however a couple of side effects recorded by those who underwent the topical treatment, including application site pain and a dry mouth.
Therapies currently available for hyperhidrosis are generally regarded as fairly ineffective and can tend to be expensive. When antiperspirants are used and fail to provide any real results, many sufferers of this excessive sweating condition turn to more aggressive alternatives, such as having Botox injections. Sufferers can also undergo laser therapy, which destroys the sweat glands.
Another treatment hyperhidrosis patients have the option of using is a device known as MiraDry. MiraDry essentially provides electromagnetic energy, which decomposes the sweat glands. Sweating can also be systematically limited through oral medicines. Localised surgery, such as liposuction, can also be used on hyperhidrosis sufferers, which can injure or remove the sweat glands.
Based on the results of the trials, Dermira has announced it is going to submit the application to the Food and Drug Administration with the aim of getting it submitted by the second half of 2017.
Hyperhidrosis affects approximately 1% of the population. The condition is caused by an overactive nervous system, which, working at an extremely high level, causes excessive sweating to occur. As HyperhidrosisUK.org notes, this condition is not temporary, and many who suffer from it have done so for years.
If you have any queries or concerns about hyperhidrosis and other vascular conditions, get in touch with Daryll baker, a Consultant Vascular Surgeon. Daryll Baker runs a vascular practice in both the NHS and privately, helping patients with vascular conditions from across Europe and the Middle East.